Company Overview

Amgen Inc. is a global biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative human therapeutics. The company operates primarily within the biotechnology and pharmaceutical industries, with a strong emphasis on biologic medicines for serious illnesses. Amgen’s core revenue is driven by branded biologic therapies and a growing portfolio of biosimilars across therapeutic areas including oncology, inflammation, cardiovascular disease, bone health, nephrology, and rare diseases. Its customers consist mainly of hospitals, specialty clinics, physicians, and healthcare systems, with end demand driven by patient populations in developed and emerging healthcare markets.

Founded in 1980, Amgen was one of the earliest biotechnology companies to successfully commercialize recombinant DNA–based medicines, beginning with therapies for anemia and neutropenia. Over time, the company evolved from a U.S.-focused biologics manufacturer into a diversified global biopharmaceutical company with large-scale manufacturing capabilities, internal research and development, and an expanding international commercial footprint. Amgen’s strategic positioning is supported by deep biologics expertise, extensive manufacturing infrastructure, and long product lifecycles protected by complex biologic production processes.

Business Operations

Amgen organizes its business around therapeutic areas rather than legally reported segments, with major commercial focus areas including Oncology, Inflammation, Cardiovascular, Bone Health, Nephrology, and Rare Diseases. Revenue is primarily generated from the sale of branded biologic medicines and biosimilars, including long-established products as well as newer therapies addressing immunology and rare conditions. The company also derives revenue from collaboration agreements, licensing arrangements, and royalties, though these represent a smaller portion of total revenue compared to product sales.

Operationally, Amgen maintains vertically integrated capabilities spanning research, clinical development, biologics manufacturing, and global distribution. The company controls a network of large-scale biologics manufacturing facilities and research centers and conducts commercial operations across both domestic and international markets. Amgen operates through wholly owned subsidiaries and regional commercial entities and has entered into select strategic partnerships for co-development and market access, particularly outside the United States.

Strategic Position & Investments

Amgen’s strategic direction centers on sustaining growth through internal research and development, lifecycle management of existing products, expansion of its biosimilars portfolio, and targeted acquisitions. A major strategic investment was the acquisition of Horizon Therapeutics plc, which significantly expanded Amgen’s presence in rare diseases and autoimmune conditions and added established revenue-generating products to its portfolio. The company continues to allocate substantial capital to late-stage clinical programs and next-generation biologics.

In addition to acquisitions, Amgen invests in emerging technologies such as advanced biologics manufacturing, novel protein engineering, and data-driven drug development. The company has also pursued selective equity investments and collaborations with biotechnology firms to access new therapeutic platforms. These initiatives are designed to diversify revenue sources, mitigate patent expiration risk, and reinforce Amgen’s competitive position in complex biologic and immunology markets.

Geographic Footprint

Amgen is headquartered in North America, with its corporate headquarters located in Thousand Oaks, California. The company has a significant operational presence across North America, Europe, and Asia-Pacific, supported by manufacturing plants, research facilities, and regional commercial organizations. The United States remains Amgen’s largest single market by revenue, reflecting the scale of biologics adoption and pricing dynamics.

Internationally, Amgen maintains strong market positions in Europe, Japan, China, and other parts of Asia-Pacific, as well as select markets in Latin America. The company’s global footprint enables participation in international healthcare systems, biosimilar tender markets, and multinational clinical development programs, contributing to diversified geographic revenue streams and long-term growth opportunities.

Leadership & Governance

Amgen was founded by George B. Rathmann, whose leadership helped establish the company as an early pioneer in commercial biotechnology. The company is led by an executive team with long tenures in biopharmaceutical development, regulatory strategy, and global operations. Amgen’s leadership emphasizes scientific rigor, long-term investment in innovation, and disciplined capital allocation aligned with shareholder returns.

Key executives include:

• Robert A. Bradway – Chairman and Chief Executive Officer
• Peter H. Griffith – Executive Vice President and Chief Financial Officer
• David M. Reese – Executive Vice President, Research and Development
• Murkbotan Murali – Executive Vice President, Global Commercial Operations
• Naveen S. Kanumalla – Senior Vice President, Corporate Development

The company operates under a governance framework aligned with U.S. public company standards, with board oversight focused on strategy, risk management, scientific investment, and compliance within regulated global healthcare markets.